Featured Research

from universities, journals, and other organizations

Biochemical Signals Associated With Atherosclerosis May Damage Other Organs

Date:
April 13, 2008
Source:
American Chemical Society
Summary:
In a finding that challenges conventional medical knowledge, researchers report that plaques formed in during atherosclerosis, or hardening of the arteries, are associated with certain harmful chemical reactions that can contribute to damage in the lungs, liver and other organs. The study suggests that the effects of the disease are more widespread than previously believed.

Biochemical signals associated with atherosclerosis may damage other organs, researchers say. Shown is a blood vessel viewed under a high-powered microscope.
Credit: National Science Foundation, Michigan State University

Many scientists view atherosclerosis, or hardening of the arteries, as a localized disease characterized by the build up of fatty plaques in the arteries, which can eventually cause heart attacks and strokes. Now, in a finding that challenges conventional knowledge, researchers in New York and North Carolina report that plaques formed in arteries are associated with certain harmful chemical reactions that can contribute to damage in the lungs, liver, and other organs.

The findings suggest that the effects of atherosclerosis are more widespread than previously believed, the researchers say. The study could lead to new targets for developing drugs that could help prevent or reduce these chemical changes that appear to accompany heart disease, the number one cause of death in the U.S. Their study was presented today at the 235th national meeting of the American Chemical Society.

"Our findings add new knowledge to the big melting pot of this complex disease called atherosclerosis," says study leader Rita Upmacis, Ph.D., a chemist at Weill Medical College of Cornell University in New York. "I anticipate that future research will establish whether the harmful protein modifications we observed in animal organs can be prevented and provide the basis of new treatments for the disease."

Scientists are closing in on the root causes of the disease. One of the more promising lines of research focuses on the interaction between certain highly reactive nitrogen molecules and proteins. Under certain conditions, this interaction produces nitrotyrosine, which has been linked to Alzheimer's, arthritis, cancer, and other disorders. However, scientists know little about the role of nitrotyrosine in atherosclerosis.

In the new study, Upmacis and colleagues worked with laboratory mice that have atherosclerosis. These mice are widely used in atherosclerosis research that cannot be done in humans. Mice that are genetically prone to atherosclerosis and fed a high-fat diet developed high levels of nitrotyrosine in their heart, lung, liver, and kidney. By contrast, mice that were fed regular diets showed no such increase. The rise in nitrotyrosine levels suggests that high-fat diets in animals with atherosclerosis can help trigger nitrotyrosine accumulation in the proteins of various organs, the scientists say.

Upmacis and colleagues also conducted a related experiment in atherosclerotic mice lacking the gene that makes nitric oxide synthase (iNOS), an enzyme that orchestrates accumulation of nitrotyrosine in proteins. In association with prior findings that iNOS gene deletion limits the formation of atherosclerotic plaques, the new study showed that nitrotyrosine accumulation in proteins is reduced in diverse organs when iNOS is absent.

"The findings support an emerging view that iNOS could be a new target for treating atherosclerosis and that limiting nitrotyrosine accumulation in the lungs, liver, and other organs could help fight the damaging effects of the disease," Upmacis says. "But the trick will be to develop a drug to block this pathway without causing any unwanted side effects."

Potentially, the accumulation of nitrotyrosine in the blood can be utilized as a diagnostic test to track atherosclerosis and provide a clearer picture of damage to organs, the researchers say.

Funding for the study was provided by the National Institutes of Health and Philip Morris (USA and International).


Story Source:

The above story is based on materials provided by American Chemical Society. Note: Materials may be edited for content and length.


Cite This Page:

American Chemical Society. "Biochemical Signals Associated With Atherosclerosis May Damage Other Organs." ScienceDaily. ScienceDaily, 13 April 2008. <www.sciencedaily.com/releases/2008/04/080409151843.htm>.
American Chemical Society. (2008, April 13). Biochemical Signals Associated With Atherosclerosis May Damage Other Organs. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2008/04/080409151843.htm
American Chemical Society. "Biochemical Signals Associated With Atherosclerosis May Damage Other Organs." ScienceDaily. www.sciencedaily.com/releases/2008/04/080409151843.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins